Skip to content
Advertisement

Vials of AstraZeneca's COVISHIELD vaccine for COVID-19 are seen at a filling lab at the Serum Institute of India, Pune, India, Thursday, Jan. 21, 2021. Experts say there is a pressing need for India to bolster vaccination, which started sluggishly in January. The country is expanding its drive to include everyone over 45 from Thursday, April 1. Spotlight on Serum Institute of India - the world’s largest maker of vaccines and key global supplier - to cater to cases at home has resulted in delays of global shipments of up to 90 million doses under the U.N.-backed COVAX program, an initiative devised to give countries access to vaccines regardless of their wealth. (AP Photo/Rafiq Maqbool)

Vials of AstraZeneca's COVISHIELD vaccine for COVID-19 are seen at a filling lab at the Serum Institute of India, Pune, India, Thursday, Jan. 21, 2021. Experts say there is a pressing need for India to bolster vaccination, which started sluggishly in January. The country is expanding its drive to include everyone over 45 from Thursday, April 1. Spotlight on Serum Institute of India - the world’s largest maker of vaccines and key global supplier - to cater to cases at home has resulted in delays of global shipments of up to 90 million doses under the U.N.-backed COVAX program, an initiative devised to give countries access to vaccines regardless of their wealth. (AP Photo/Rafiq Maqbool)

Featured Photo Galleries